Barring unforeseen rivals, Imricor will have a 100 per cent share of the MRI-guided cardiac catheter ablation market, writes ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

The prevalence of PH was 12.8% in those hospitalized in 2018 with left heart disease, a lower percentage than found in previous research.

IMR is currently undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial supporting US FDA ...

Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

The Affera mapping and ablation system is the first on the market that can deliver both pulsed-field and radiofrequency ...

In the U.S., the approval covers the treatment of the irregular heartbeats caused by persistent afib as well as the ... isthmus-dependent atrial flutter. "The Affera system was designed to address ...

This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.